Login to Your Account

Following FDA Panel, Cephalon Expects Provigil Label Expansion

By Kim Coghill

Friday, September 26, 2003
BETHESDA, Md. - An FDA advisory panel unanimously agreed that Cephalon Inc.'s wake-promoting agent, Provigil, is effective in treating excessive sleepiness associated with sleep apnea. And in a 6-2 vote, the panel said Cephalon's data supported the claim that Provigil is effective in the treatment of excessive sleepiness in patients with shift-worker sleep disorder. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription